<DOC>
	<DOCNO>NCT01415440</DOCNO>
	<brief_summary>The aim study examine mechanism stimulant medication reduce symptom patient Attention Deficit Hyperactivity Disorder ( ADHD ) . Using Magnetic Resonance Imaging ( MRI ) , investigator find volumes certain brain region reduce patient ADHD . The reduced volume much less pronounced patient treat stimulant medication , suggest stimulant may reduce symptom ADHD reverse volume reduction . In second related study , investigator find patient ADHD , emotional processing normalized patient take stimulant medication . Both study point possible mechanisms stimulant effective ; however , significant limitation finding derive cross-sectional study . In current study , investigator hope replicate treatment effect stimulant prospective , controlled manner . The investigator plan measure ADHD symptom severity patient 12-weeks controlled treatment either stimulant medication placebo utilizing structural functional MRI . Combining image randomize controlled trial allow u good ass effect stimulant brain function structure .</brief_summary>
	<brief_title>Imaging Effects Stimulant Medication Emotional Lability Patients With ADHD</brief_title>
	<detailed_description>A cohort 100 patient ADHD recruit 12 week , double-blind , parallel , randomize control trial Lisdexamfetamine ( Vyvanse ) versus placebo , 50 patient randomized Lisdexamfetamine 50 patient placebo . The investigator acquire high-resolution , anatomical functional MRI image baseline 12 week treatment . In addition , 75 age- sex-matched healthy control subject image baseline .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>ADHD Participants : Meets Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD , subtype . Healthy Control Participants : No current DSMIVTR Axis I psychiatric diagnosis . All Participants : 1 . Male female , 6 25 year age , good physical health 2 . Englishspeaking 1 . Current comorbid DSMIVTR Axis I psychiatric diagnosis symptomatic manifestation , opinion examine physician , contraindicate Lisdexamfetamine treatment confound safety assessment 2 . Meets DSMIVTR criterion active substance abuse and/or dependence 3 . Lifetime history cocaine stimulant abuse dependence 4 . Actively suicidal 5 . Children adolescent : Prior treatment psychostimulants longer 1 month duration and/or treatment psychostimulants within past 4 month Adults : Treatment psychostimulants within past 12 month . 6 . Documented allergy intolerance Lisdexamfetamine stimulant medication . 7 . Taking medication central nervous system effect . 8 . History seizure ( febrile seizure ) 9 . Diagnosis hyperthyroidism , glaucoma , serious medical illness . 10 . Personal family history medical condition , cardiovascular disease , may interfere study participation , treatment Lisdexamfetamine may pose risk 11 . Pregnant lactate 12 . MRI contraindication pacemaker , brace , etc . 13 . Full scale intelligence quotient ( FSIQ ) less 70</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Vyvanse</keyword>
	<keyword>stimulant medication</keyword>
	<keyword>ADD</keyword>
</DOC>